pharmaceuticals
Jump to
80 Results Found
  • Cadila Health Standalone September 2020 Net Sales at Rs 2,056.90 crore, up 22.24% Y-o-Y Nov 03, 2020 09:22 AM IST

    Cadila Health Standalone September 2020 Net Sales at Rs 2,056.90 crore, up 22.24% Y-o-Y

  • Cadila Health Consolidated September 2020 Net Sales at Rs 3,820.00 crore, up 13.47% Y-o-Y Nov 03, 2020 09:11 AM IST

    Cadila Health Consolidated September 2020 Net Sales at Rs 3,820.00 crore, up 13.47% Y-o-Y

  • Cadila Health Consolidated June 2020 Net Sales at Rs 3,639.90 crore, up 4.11% Y-o-Y Aug 05, 2020 07:11 PM IST

    Cadila Health Consolidated June 2020 Net Sales at Rs 3,639.90 crore, up 4.11% Y-o-Y

  • Cadila Health Standalone June 2020 Net Sales at Rs 1,795.90 crore, up 33.64% Y-o-Y Aug 05, 2020 07:11 PM IST

    Cadila Health Standalone June 2020 Net Sales at Rs 1,795.90 crore, up 33.64% Y-o-Y

  • Hikal Standalone June 2020 Net Sales at Rs 352.77 crore, down 12.5% Y-o-Y Aug 05, 2020 09:25 AM IST

    Hikal Standalone June 2020 Net Sales at Rs 352.77 crore, down 12.5% Y-o-Y

  • Hikal Consolidated June 2020 Net Sales at Rs 352.77 crore, down 12.5% Y-o-Y Aug 05, 2020 09:25 AM IST

    Hikal Consolidated June 2020 Net Sales at Rs 352.77 crore, down 12.5% Y-o-Y

  • Sun Pharma Consolidated June 2020 Net Sales at Rs 7,585.25 crore, down 9.42% Y-o-Y Aug 03, 2020 09:25 AM IST

    Sun Pharma Consolidated June 2020 Net Sales at Rs 7,585.25 crore, down 9.42% Y-o-Y

  • Sun Pharma Standalone June 2020 Net Sales at Rs 2,963.04 crore, down 10.46% Y-o-Y Aug 03, 2020 09:22 AM IST

    Sun Pharma Standalone June 2020 Net Sales at Rs 2,963.04 crore, down 10.46% Y-o-Y

  • Dr Reddys Labs Standalone June 2020 Net Sales at Rs 3,244.40 crore, up 29.33% Y-o-Y Jul 29, 2020 10:45 PM IST

    Dr Reddys Labs Standalone June 2020 Net Sales at Rs 3,244.40 crore, up 29.33% Y-o-Y

  • Dr Reddys Labs Consolidated June 2020 Net Sales at Rs 4,426.50 crore, up 14.73% Y-o-Y Jul 29, 2020 10:45 PM IST

    Dr Reddys Labs Consolidated June 2020 Net Sales at Rs 4,426.50 crore, up 14.73% Y-o-Y

  • Fermenta Bio Consolidated March 2020 Net Sales at Rs 64.54 crore, down 29.53% Y-o-Y Jun 30, 2020 11:00 AM IST

    Fermenta Bio Consolidated March 2020 Net Sales at Rs 64.54 crore, down 29.53% Y-o-Y

  • Dr Reddys Labs Consolidated March 2020 Net Sales at Rs 4,448.90 crore, up 10.41% Y-o-Y May 21, 2020 09:13 AM IST

    Dr Reddys Labs Consolidated March 2020 Net Sales at Rs 4,448.90 crore, up 10.41% Y-o-Y

  • COVID-19 treatment | Indian drug makers gearing up to make Gilead's remdesivir: Report May 14, 2020 11:01 AM IST

    COVID-19 treatment | Indian drug makers gearing up to make Gilead's remdesivir: Report

    Under a licensing agreement, these companies have the right to receive a technology transfer of Gilead's manufacturing process for remdesivir to enable them to scale up production quicker.

  • Coronavirus crisis | These four COVID-19 vaccines are ahead of the pack May 10, 2020 03:15 PM IST

    Coronavirus crisis | These four COVID-19 vaccines are ahead of the pack

    Over 100 potential COVID-19 vaccines are currently under development, but four are ahead of the pack.

  • Reporter's Take | COVID-19 could be India’s chance to end reliance on China for drug raw material Mar 02, 2020 09:12 PM IST

    Reporter's Take | COVID-19 could be India’s chance to end reliance on China for drug raw material

    Moneycontrol's Shraddha Sharma talks to Viswanath Pilla to understand the problem of drug shortage in Indian pharmacy due to slowdown in China production.

  • Pharma department moves to wrestle NPPA’s special powers to cap drug prices Sep 10, 2017 10:12 AM IST

    Pharma department moves to wrestle NPPA’s special powers to cap drug prices

    In simple terms, Paragraph 19 of the DPCO allows the pricing authority to fix or revise the ceiling price or retail price of any drug which it deems necessary for the interest of the public in case of any extraordinary circumstances.

  • Omkar Speciality Chemicals to expand business operations Jul 04, 2017 08:05 AM IST

    Omkar Speciality Chemicals to expand business operations

    The company said it would further like to penetrate into segments like fragrances and flavours, food and beverages, etc. in which new products will be launched in the immediate future.

  • Getting GST ready: Is the pharma industry ready? Jun 14, 2017 06:57 PM IST

    Getting GST ready: Is the pharma industry ready?

    The goods and services tax rollout is around the corner. How is the pharmaceutical industry preparing for this? Yash Jain and Archana Shukla gave us this ground report from Indore and Mumbai.

  • Watch: MSME Leadership Series Apr 04, 2017 12:02 PM IST

    Watch: MSME Leadership Series

    This Season 2 episode of MSME Leadership Series held at Visakhapatnam because it is home to a wide range of industries right from heavy industries to pharmaceuticals to industrial minerals to fishing.

  • Earnings to be next trigger for market; steer clear of Bharat Fin: Dimensions Chief Mar 23, 2017 10:32 AM IST

    Earnings to be next trigger for market; steer clear of Bharat Fin: Dimensions Chief

    Ajay Srivastava of Dimensions Consulting feels the earnings trajectory could determine the direction in which the market will move going forward. He is positive on oil marketing companies.

  • Alembic Pharma soars 7% on USFDA inspection clearance Mar 10, 2017 02:48 PM IST

    Alembic Pharma soars 7% on USFDA inspection clearance

    The US drug regulator had inspected its Baroda unit between March 6 and 10 and issued no Form 483s for the same.

  • Dr Reddy's slips 3.5% on 13 USFDA observations for Duvvuda unit Mar 09, 2017 09:28 AM IST

    Dr Reddy's slips 3.5% on 13 USFDA observations for Duvvuda unit

    The US drug regulator issued the observations for its oncology formulation facility at Duvvuda in Visakhapatnam‘s SEZ. The site is important given Dr Reddy‘s focus on complex generic filings.

  • Biocon jumps 5% on HC nod to make & sell cancer drug Mar 03, 2017 01:59 PM IST

    Biocon jumps 5% on HC nod to make & sell cancer drug

    The court allowed the firm to make and sell Canmab, a cancer drug of the company. Stock was under pressure so far on the back of inspection reports. The management, earlier this morning, stated the inspections were expected as its dossiers were accepted by US FDA and EMA.

  • Base effect in metals, PSBs may aid Q3 earnings: Edelweiss Jan 09, 2017 10:00 AM IST

    Base effect in metals, PSBs may aid Q3 earnings: Edelweiss

    Valuation in the information technology sector is favourable but challenges in terms of earnings and uncertainty on Trump‘s policies make them good picks only on bad days, says Nischal Maheshwari, Head - Institutional Equities at Edelweiss Securities.

  • SME Exchange: Journey so far of India's most promising SMEs Oct 19, 2016 03:57 PM IST

    SME Exchange: Journey so far of India's most promising SMEs

    SME Exchange is a special series that focuses on some of India's most promising small and medium enterprises and brings you their inspiring success stories. This episode showcases three diverse companies from the sectors of telecom, pharmaceuticals and construction and home decor. Find out more about these three entrepreneurs and their journeys.

Sections